Skip to content


NeonMind’s Pharmaceutical Division is advancing two independent, psilocybin-based treatments for obesity that act on different mechanisms to promote weight management and induce lasting lifestyle changes.

NeonMind is developing the first and only novel psilocybin-based drug candidates targeting obesity. NeonMind’s lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind has an additional pipeline opportunity, NEO-002, which employs low-dose psilocybin to control appetite.

Weight Management Program Pipeline

NeonMind has two novel therapies currently in preclinical trials, targeting the 5-HT2A and 5-HT2C receptors, respectively. We expect these treatments to begin Phase 2 Human Clinical Trials in Q2 2022.

Obesity has become a public health crisis. Despite growing evidence that obesity is a serious chronic disease, our current health system and the treatment options presently available are simply not effective.. Health professionals feel ill-equipped to support people living with this complex condition. People with obesity experience higher rates of:

  • Type 2 diabetes
  • Gallbladder disease
  • Fatty liver disease
  • Gout
  • Cancer
  • Increased rates of morbidity and mortality

By exploring novel ways to address this health crisis, obesity can be overcome through effective weight management treatments and proper mental health support. By providing this, people can truly improve their physical and mental health as well as their overall wellness and quality of life.

Our preclinical results in an animal model showed that psilocybin reduced weight gain by 31% and 28% for low and high dose psilocybin, respectively, relative to placebo. Significant reduction in weight gain was seen by day 4 for both treatments. 

Intellectual Property Portfolio

Our intellectual property applications covers a wide range of psilocybin-derived compounds and surrounds the spectrum of weight management conditions. We have eleven U.S. provisional and four Patent Cooperation Treaty (PCT) applications filed to date, with potential rights in 152 countries.